专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO1998020792A1 APPARATUS AND METHODS FOR ANALYZING BODY SOUNDS 审中-公开
标题翻译：用于分析身体声音的装置和方法
公开(公告)号：WO1998020792A1
公开(公告)日：1998-05-22
申请号：PCT/US1997021185
申请日：1997-11-13
申请人： UNIVERSITY TECHNOLOGY CORPORATION
发明人： UNIVERSITY TECHNOLOGY CORPORATION , SHAPIRO, Joseph, Isaac , WEINBERGER, Howard, David
IPC分类号： A61B05/02
CPC分类号： A61B7/04 , A61B5/0456 , A61B5/7203 , A61B5/7257 , A61B5/726 , A61B7/003
摘要： This invention is an apparatus and method for assisting an operator to diagnose physical conditions in a patient by collecting and analyzing cyclical body sounds such as heart beat, peripheral vessel sounds, or breath sounds. Several cycles of data are collected by sound detector (12) and digitized by an analog to digital converter (28). Each cycle is converted to the frequency domain (102), and phase fixed (104). Then all of the frequency converted and phase fixed cycles are signal averaged (106) together, and the results displayed (108) to the operator. The cycles may be sorted according to respiratory cycle (204, 304, 404), and averaged (210, 310, 410) in two groups. The cycles may be gated according to the patients ECG (206). The apparatus may also suggest diagnoses (218, 318, 418) or further maneuvers (214) to be performed.
摘要翻译：本发明是一种用于通过收集和分析周期性身体声音（例如心跳，外周血管声音或呼吸音）来帮助操作者诊断患者身体状况的装置和方法。由声音检测器（12）收集几个数据周期，并由模数转换器（28）数字化。每个周期被转换为频域（102），相位固定（104）。然后将所有频率转换和相位固定周期信号平均化（106），结果显示（108）给操作员。循环可以根据呼吸周期（204,304,404）和平均值（210,310,410）进行分类。循环可以根据患者心电图门控（206）。该装置还可以建议要执行的诊断（218,318,418）或进一步的操纵（214）。

22. 发明申请

WO1998010649A1 BIOCOMPATIBLE CATIONIC DETERGENTS AND USES THEREFOR 审中-公开
标题翻译：生物化学阳离子洗涤剂及其用途
公开(公告)号：WO1998010649A1
公开(公告)日：1998-03-19
申请号：PCT/US1997016181
申请日：1997-09-11
申请人： UNIVERSITY TECHNOLOGY CORPORATION
发明人： UNIVERSITY TECHNOLOGY CORPORATION , SHEFTER, Eli , RUTH, James, A. , MEYER, Jeffery, D. , MANNING, Mark, C. , KROLL, David, J. , CLAFFEY, David, J.
IPC分类号： A01N37/12
CPC分类号： B82Y5/00 , A61K9/0073 , A61K9/1647 , A61K9/1694 , A61K9/5123 , A61K9/5153 , A61K9/5192 , A61K38/046 , A61K38/09 , A61K38/10 , A61K38/11 , A61K38/27 , A61K38/28 , A61K38/57 , A61K47/183 , A61K47/28 , A61K47/541 , A61K47/6927 , B01F3/0092 , B01F2003/0064 , C07J41/0055 , C07K1/32 , Y02P20/544
摘要： Provided is a method for preparing a true, homogeneous solution of a pharmaceutical substance dissolved in an organic solvent in which the pharmaceutical substance is not normally soluble. Solubilization is obtained by forming a hydrophobic ion pair complex involving the pharmaceutical substance and an amphiphilic material. The resulting organic solution may be further processed to prepare pharmaceutical powders. A biodegradable polymer may be co-dissolved with the pharmaceutical substance and the amphiphilic material and may be incorporated into a pharmaceutical powder. A preferred method for preparing pharmaceutical powders is to subject the organic solution to gas antisolvent precipitation using a supercritical gas antisolvent such as carbon dioxide. Also provided is a method for making hollow particles having a fiber-like shape which would provide enhanced retention time in the stomach if ingested by a human or animal host. Further provided are novel biocompatible cationic surfactants and uses therefor, including the delivery, in vitro and in vivo, of nucleic acids into cells to transform the cells.
摘要翻译：提供了制备溶解在药物通常不溶于其中的有机溶剂中的药物的真实均匀溶液的方法。通过形成涉及药物物质和两亲性物质的疏水性离子对络合物来获得溶解。所得到的有机溶液可以进一步加工以制备药物粉末。可生物降解的聚合物可以与药物物质和两亲物质共溶解，并且可以并入药物粉末中。用于制备药物粉末的优选方法是使用超临界气体反溶剂如二氧化碳使有机溶液进行气体反溶剂沉淀。还提供了一种制备具有纤维状形状的中空颗粒的方法，其将在由人或动物宿主摄取的情况下在胃中提供增强的停留时间。还提供了新的生物相容性阳离子表面活性剂及其用途，包括将体外和体内的核酸递送入细胞以转化细胞。

23. 发明申请

WO1997022005A1 SERUM FERRITIN AS A PREDICTOR OF THE ACUTE RESPIRATORY DISTRESS SYNDROME 审中-公开
标题翻译：作为急性呼吸道综合征患者的血清白蛋白
公开(公告)号：WO1997022005A1
公开(公告)日：1997-06-19
申请号：PCT/US1996019884
申请日：1996-12-12
申请人： UNIVERSITY TECHNOLOGY CORPORATION , REPINE, John, E.
发明人： UNIVERSITY TECHNOLOGY CORPORATION
IPC分类号： G01N33/68
CPC分类号： G01N33/68 , Y10S435/975
摘要： The invention relates to the discovery that serum ferritin concentrations are elevated in patients at risk for the development of Acute Respiratory Distress Syndrome (ARDS) and who subsequently develop ARDS, as compared to at-risk patients who do not subsequently develop ARDS. Thus, the invention includes a method for determining ARDS development potential in an at-risk patient comprising the steps of determining the patient's serum concentration of frritin and determining ARDS development potential from said serum concentration of ferritin.
摘要翻译：本发明涉及到发现急性呼吸窘迫综合征（ARDS）并随后发展ARDS风险的患者的血清铁蛋白浓度升高，与不随后发展ARDS的风险患者相比，血清铁蛋白浓度升高。因此，本发明包括确定危险患者ARDS发展潜力的方法，包括以下步骤：从所述血清铁蛋白浓度确定患者血清Frritin浓度并确定ARDS发展潜能。

24. 发明申请

US20040097454A1 Method for modulation of cell phenotype 审中-公开
标题翻译：调节细胞表型的方法
公开(公告)号：US20040097454A1
公开(公告)日：2004-05-20
申请号：US10431598
申请日：2003-05-06
申请人： University Technology Corporation , National Jewish Medical and Research Center , U.S. Government as represented by the Department of Veterans Affairs
发明人： Jane E. Reusch , Dwight J. Klemm
IPC分类号： A61K048/00 , C12Q001/68
CPC分类号： C07K14/4705 , A61K48/00
摘要： Described is a method for modulating the phenotype of a cell, and particularly, of a target cell in a patient who has or is at risk of developing a disease or condition in which is associated with dysregulation of cellular phenotype. The method includes administration of a recombinant nucleic acid molecule encoding a protein having CREB biological activity or dominant negative CREB biological activity to a patient, in such a manner that the protein is expressed in a target cell of a patient and is sufficient to modulate the phenotype of the target cell. Such a method is particularly useful in patients who have, or at risk of developing, diabetes, obesity, macrovascular disease, heart failure, osteoarthritis, and neural diseases and conditions.
摘要翻译：描述了调节具有或具有发展与细胞表型失调相关的疾病或病症的风险的患者中的细胞，特别是靶细胞的表型的方法。该方法包括向患者施用编码具有CREB生物活性或显性负CREB生物活性的蛋白质的重组核酸分子，使得蛋白质在患者的靶细胞中表达并且足以调节表型的目标细胞。这种方法在患有糖尿病，肥胖，大血管疾病，心力衰竭，骨关节炎和神经疾病和病症的风险的患者中特别有用。

25. 发明申请

US20030134282A1 Diagnosis and treatment of myocardial failure 有权
公开(公告)号：US20030134282A1
公开(公告)日：2003-07-17
申请号：US09969086
申请日：2001-10-01
申请人： University Technology Corporation
发明人： Michael R. Bristow , Leslie A. Leinwand , Wayne Minobe , Koichi Nakao , Koichiro Kinugawa
IPC分类号： C12Q001/68 , C12P019/34 , G06F019/00 , G01N033/48 , G01N033/50
CPC分类号： C12Q1/6883 , C07K14/4716 , C12Q1/6809 , C12Q2600/158
摘要： The invention provides methods of diagnosing myocardial failure in a human. The methods comprise obtaining a sample of myocardial tissue from a ventricle of the heart of the human. In one method, the expression of null-myosin heavy chain ((null-MHC), null-myosin heavy chain (null-MHC), or both in the sample is quantitated, and it is determined by statistical analysis if the expression of null-MHC, null-MHC, or both in the sample is significantly different than their expression in normal human ventricular myocardial tissue. A second method comprises quantitating the expression of null1-thyroid hormone receptor (null1-THR), null2-THR, null1-THRnullnull1-THR, or combinations thereof in the sample, and determining by statistical analysis if the expression of null1-THR, null2-THR, or null1-THRnullnull1-THR in the sample is significantly different than their expression in normal human ventricular myocardial tissue. The invention also provides kits for diagnosing myocardial failure by these methods. The invention further provides methods of treating myocardial failure in a human. One method comprises administering an effective amount of an agent that directly causes an increase in the quantity of null-MHC in the myocardial tissue of the heart. A second method comprises administering an effective amount of an agent that directly causes an increase in the quantity of null1-THR, an increase in the quantity of null1-THR, a decrease in the quantity of (null2-THR, or combinations thereof, in the myocardial tissue of the heart. Finally, the invention provides a method of quantitating the expression of a first protein relative to the expression of a second protein or to the total expression of the first and second proteins. The method comprises obtaining a sample of cells or tissue expressing the first protein and the second protein, extracting RNA from the cells or tissue, preparing cDNA from the RNA, amplifying the cDNA coding for the first and second proteins by polymerase chain reaction using primers that hybridize to cDNA coding for the first protein, the second protein or both, and quantitating the amplified PCR products.

26. 发明申请

US20030125294A1 Selective toxin expression in angiogenic endothelial cells 审中-公开
标题翻译：血管生成内皮细胞中的选择性毒素表达
公开(公告)号：US20030125294A1
公开(公告)日：2003-07-03
申请号：US10294903
申请日：2002-11-15
申请人： University Technology Corporation
发明人： Ian H. Maxwell , Francoise Maxwell , Cortina Kaletta , Kurt W. Naujoks
IPC分类号： A61K048/00 , C07H021/04
CPC分类号： C07K14/34 , A61K48/00 , C12N15/85 , C12N2799/027 , C12N2830/00 , C12N2830/002 , C12N2830/008 , C12N2830/60 , C12N2830/85
摘要： The present invention relates to pharmaceutical compositions capable of specifically inducing cell death in the proliferating angiogenic endothelial cells associated with solid tumors and other angiogenesis associated diseases. More specifically, the present invention relates to nucleotide constructs that are selectively active in angiogenic endothelial cells and that encode highly toxic agents, such as diphtheria toxin, for expression in such cells.
摘要翻译：本发明涉及能够在与实体瘤和其他血管生成相关疾病相关的增殖性血管生成内皮细胞中特异性诱导细胞死亡的药物组合物。更具体地，本发明涉及在血管生成内皮细胞中选择性活性并且编码高毒性剂如白喉毒素用于在这样的细胞中表达的核苷酸构建体。

27. 发明申请

US20030113271A1 Formulations for pulmonary delivery 审中-公开
标题翻译：用于肺部输送的制剂
公开(公告)号：US20030113271A1
公开(公告)日：2003-06-19
申请号：US10327476
申请日：2002-12-24
申请人： University Technology Corporation
发明人： Derrick Katyama , Mark C. Manning , Kathleen A. Stringer , John E. Repine
IPC分类号： A61L009/04 , A61K038/48
CPC分类号： C12N9/6462 , A61K38/49 , C12N9/6459 , C12Y304/21069 , C12Y304/21073
摘要： Formulations for pulmonary delivery that include a protein and a non-physiological surfactant at or above the CMC of the surfactant, and methods for preparing and using the same.
摘要翻译：用于肺部递送的制剂，其包含在表面活性剂的CMC上或上述蛋白质和非生理学表面活性剂，以及制备和使用它们的方法。

28. 发明申请

US20020025327A1 Use of neurotoxin therapy for treatment of urologic and related disorders 有权
公开(公告)号：US20020025327A1
公开(公告)日：2002-02-28
申请号：US09978982
申请日：2001-10-15
申请人： University Technology Corporation
发明人： Richard A. Schmidt
IPC分类号： A61K039/08 , A61K038/00
CPC分类号： A61K38/4893 , A61K31/165 , A61K31/529 , A61K38/1703
摘要： The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.

29. 发明申请

US20040247613A1 Treating cancer using a telomerase vaccine 有权
标题翻译：使用端粒酶疫苗治疗癌症
公开(公告)号：US20040247613A1
公开(公告)日：2004-12-09
申请号：US10877022
申请日：2004-06-24
申请人： GERON CORPORATION , UNIVERSITY TECHNOLOGY CORPORATION
发明人： Thomas R. Cech , Joachim Lingner , Toru Nakamura , Karen B. Chapman , Gregg B. Morin , Calvin B. Harley , William H. Andrews
IPC分类号： A61K039/00
CPC分类号： C12N15/1137 , A01K2217/05 , A61K38/00 , A61K39/00 , A61K48/00 , C07K2319/00 , C12N9/1241 , C12N9/1276 , C12N15/113 , C12N2310/15 , C12N2310/315 , C12Q1/6886 , C12Q2600/158 , C12Y207/07049
摘要： The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
摘要翻译：本发明提供了与人类端粒酶逆转录酶（hTRT），人端粒酶的催化蛋白质亚基相关的组合物和方法。本发明的多核苷酸和多肽可用于人类疾病的诊断，预后和治疗，用于改变细胞和生物体的增殖能力，以及用于鉴定和筛选用于治疗诸如癌症的疾病的化合物和治疗。

30. 发明申请

US20020132007A1 Sustainded-release composition including amorphous polymer 有权
标题翻译：包括无定形聚合物的持久释放组合物
公开(公告)号：US20020132007A1
公开(公告)日：2002-09-19
申请号：US09877330
申请日：2001-06-07
申请人： University Technology Corporation
发明人： Theodore W. Randolph , Mark C. Manning , Richard F. Falk
IPC分类号： A61K009/14
CPC分类号： A61K9/1694 , A61K47/541 , A61K47/554 , Y10S514/937 , Y10S514/951
摘要： Provided is a sustained release composition for sustained release of a pharmaceutical substance. The composition includes a biocompatible polymer that is highly amorphous and a pharmaceutical substance in a hydrophobic ion complex with an amphiphilic material. Also provided a compressed antisolvent method for manufacturing the composition, various product forms incorporating the composition and various uses for the composition.
摘要翻译：提供用于药物物质的持续释放的持续释放组合物。该组合物包括高度无定形的生物相容性聚合物和与两亲性物质在疏水性离子络合物中的药物。还提供了用于制造组合物的压缩抗溶剂方法，包含组合物的各种产品形式和用于组合物的各种用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式